Post by AKT Health Inc.

#RegulatoryAffairs teams get pulled into a study two years late, and then get asked why the endpoints don't match what the #authority wants to see That gap is one of the most preventable problems we run into. #ClinicalDevelopment and #RegulatoryAffairs are still run as two separate workstreams in many organizations with different timelines, different owners, and no real conversation until the dossier is being assembled. But by the time a study is designed, half the regulatory pathway is already decided: what endpoints you choose, how you collect the data, and what documentation exists to back it up. Get #RA into the room during study design, and a few things change: - Fewer avoidable questions come back during review - Evidence gets generated to match what regulators actually expect, not what gets discovered too late - Submissions come out more consistently, with fewer gaps to patch - #Marketaccess and #Reimbursement conversations have a stronger foundation to build on Regulatory strategy isn't a document-prep function bolted on at the end. Done right, it's the thing that turns clinical evidence into an approved product and eventually, into something patients can actually access. We're breaking down how Regulatory Affairs connects to every stage of the product lifecycle. #RegulatoryAffairs #ClinicalDevelopment #LifeSciences #MedicalDevices #MarketAccess #AKTHealth #RegTech